Results 81 to 90 of about 74,242 (343)

Cyclin B1/CDK1-regulated mitochondrial bioenergetics in cell cycle progression and tumor resistance.

Cancer Letters, 2019
A mammalian cell houses two genomes located separately in the nucleus and mitochondria. During evolution, communications and adaptations between these two genomes occur extensively to achieve and sustain homeostasis for cellular functions and ...
B. Xie, Shuangyan Wang, Nian Jiang, Jian Jian Li   +3 more
semanticscholar   +1 more source

Cyclin A–CDK1 suppresses the expression of the CDK1 activator CDC25A to safeguard timely mitotic entry

Journal of Biological Chemistry, 2023
Cyclin A and CDC25A are both activators of cyclin-dependent kinases (CDKs): cyclin A acts as an activating subunit of CDKs and CDC25A a phosphatase of the inhibitory phosphorylation sites of the CDKs. In this study, we uncovered an inverse relationship between the two CDK activators.
Lau Yan Ng, Hoi Tang Ma, Randy Y.C. Poon
openaire   +3 more sources

Brain-derived neurotrophic factor-dependent cdk1 inhibition prevents G2/M progression in differentiating tetraploid neurons. [PDF]

PLoS ONE, 2013
Neurodegeneration is often associated with DNA synthesis in neurons, the latter usually remaining for a long time as tetraploid cells before dying by apoptosis.
María C Ovejero-Benito, José M Frade
doaj   +1 more source

Global phosphoproteomics reveals DYRK1A regulates CDK1 activity in glioblastoma cells

Cell Death Discovery, 2021
Both tumour suppressive and oncogenic functions have been reported for dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A). Herein, we performed a detailed investigation to delineate the role of DYRK1A in glioblastoma.
A. Recasens, Sean J. Humphrey, Michael Ellis, Monira Hoque, Ramzi H. Abbassi, Brianna Chen, Mitchell Longworth, E. Needham, D. James, T. Johns, B. Day, M. Kassiou, Pengyi Yang, L. Munoz   +13 more
semanticscholar   +1 more source

Nuclear HuR accumulation through phosphorylation by Cdk1 [PDF]

Genes & Development, 2008
A predominantly nuclear RNA-binding protein, HuR translocates to the cytoplasm in response to stress and proliferative signals, where it stabilizes or modulates the translation of target mRNAs. Here, we present evidence that HuR phosphorylation at S202 by the G2-phase kinase Cdk1 influences its subcellular distribution.
Hyeon Ho, Kim, Kotb, Abdelmohsen, Ashish, Lal, Rudolf, Pullmann, Xiaoling, Yang, Stefanie, Galban, Subramanya, Srikantan, Jennifer L, Martindale, Justin, Blethrow, Kevan M, Shokat, Myriam, Gorospe   +10 more
openaire   +2 more sources

MicroRNAs and target genes as regulators of colon cancer immune signaling

Медицинская иммунология
Colorectal cancer (CRC) is among the most common oncological diseases in the world, associated with a high mortality rate. Recently, immunotherapeutic approaches to the treatment of CRC have been developed, which have enabled achievement of long-term and
O. I. Kit, D. Yu. Gvaldin, N. A. Petrusenko, N. N. Timoshkina, D. A. Savchenko, I. A. Novikova   +5 more
doaj   +1 more source

The laminA/NF-Y protein complex reveals an unknown transcriptional mechanism on cell proliferation [PDF]

, 2016
Lamin A is a component of the nuclear matrix that also controls proliferation by largely unknown mechanisms. NF-Y is a ubiquitous protein involved in cell proliferation composed of three subunits (-YA -YB -YC) all required for the DNA ...
Alonzi, Tonino, Capogrossi, Maurizio C., Carlomosti, Fabrizio, Ciana, Paolo, Cicchillitti, Lucia, Dell'Anna, Maria Lucia, Dell'Omo, Giulia, Gurtner, Aymone, Magenta, Alessandra, Mancone, Carmine, Manni, Isabella, Piaggio, Giulia, Picardo, Mauro, Regazzo, Giulia, Rizzo, Maria Giulia, Spagnuolo, Manuela, Tripodi, Marco   +16 more
core   +2 more sources

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Inhibition of CDK1 Reverses the Resistance of 5-Fu in Colorectal Cancer

Cancer Management and Research, 2020
Yiping Zhu,1 Kai Li,2 Jieling Zhang,2 Lu Wang,1 Lili Sheng,1 Liang Yan2 1Department of Oncology, The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, People’s Republic of China; 2Provincial Key Laboratory of Biological Macro ...
Zhu Y, Li K, Zhang J, Wang L, Sheng L, Yan L   +5 more
doaj  

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer

Molecular Oncology, EarlyView.
Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni, Antonella Palmese, Stefano Scalera, Laura Cipriani, Davide Mascolo, Patrizia Vici, Teresa Arcuri, Lorena Filomeno, Eriseld Krasniqi, Giovanni Blandino, Giulia Bon, Marcello Maugeri‐Saccà   +11 more
wiley   +1 more source